Baidu (BIDU) has achieved a significant milestone as it seeks to leverage computational biology strengths in enhancing mRNA vaccine and therapy designs. The company has reached an agreement that will see Sanofi (SNY) integrate Baidu's mRNA design optimization platform, LinearDesign, into Sanofi's product design pipeline. BIDU shares fell 2.61% to close at $147.81 on November 22. Baidu is a Chinese AI and internet company that offers internet related services and online marketing solutions. The company operates through Baidu Core and iQIYI segments. Baidu- Sanofi Partnership The integration will pave the way for Sanofi to use the LinearDesign platform to optimize mRNA sequences in human therapies and in preventive uses.
https://www.tipranks.com/news/baidu-partners-with-sanofi-on-vaccine-development?utm_source=advfn.com&utm_medium=referral